RIM
ANIP icon

Ranger Investment Management’s ANI Pharmaceuticals ANIP Stock Holding History

Ranger Investment Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.7M Sell
360,083
-2,295
-0.6% -$179K 2% 13
2025
Q4 		$28.6M Buy
362,378
+91,033
+34% +$7.88M 1.96% 13
2025
Q3 		$24.9M Sell
271,345
-262,888
-49% -$21.4M 1.73% 26
2025
Q2 		$34.9M Sell
534,233
-37,405
-7% -$2.44M 2.43% 7
2025
Q1 		$38.3M Sell
571,638
-6,100
-1% -$364K 2.74% 8
2024
Q4 		$31.9M Sell
577,738
-11,950
-2% -$686K 2.02% 16
2024
Q3 		$35.2M Buy
589,688
+186,954
+46% +$11.4M 2.26% 11
2024
Q2 		$25.6M Buy
402,734
+530
+0.1% +$34.4K 1.74% 24
2024
Q1 		$27.8M Sell
402,204
-32,413
-7% -$1.96M 1.79% 23
2023
Q4 		$24M Buy
434,617
+7,769
+2% +$428K 1.45% 37
2023
Q3 		$24.8M Sell
426,848
-18,309
-4% -$1.06M 1.65% 25
2023
Q2 		$24M Buy
445,157
+319,601
+255% +$14.2M 1.44% 34
2023
Q1 		$4.99M Buy
125,556
+4,370
+4% +$184K 0.33% 60
2022
Q4 		$4.88M Buy
121,186
+2,676
+2% +$101K 0.36% 66
2022
Q3 		$3.81M Sell
118,510
-2,131
-2% -$72.9K 0.3% 69
2022
Q2 		$3.58M Buy
120,641
+2,840
+2% +$81.9K 0.27% 68
2022
Q1 		$3.31M Buy
117,801
+7,050
+6% +$263K 0.21% 70
2021
Q4 		$5.1M Buy
110,751
+25
+0% +$1.07K 0.28% 64
2021
Q3 		$3.63M Buy
110,726
+5,785
+6% +$180K 0.19% 76
2021
Q2 		$3.68M Sell
104,941
-440
-0.4% -$15K 0.19% 74
2021
Q1 		$3.81M Sell
105,381
-1,421
-1% -$44.5K 0.21% 76
2020
Q4 		$3.1M Sell
106,802
-17,961
-14% -$514K 0.16% 72
2020
Q3 		$3.52M Buy
124,763
+55,527
+80% +$1.65M 0.22% 64
2020
Q2 		$2.24M Sell
69,236
-27,875
-29% -$999K 0.15% 71
2020
Q1 		$3.96M Buy
97,111
+6,772
+7% +$360K 0.35% 57
2019
Q4 		$5.57M Sell
90,339
-3,325
-4% -$220K 0.37% 56
2019
Q3 		$6.83M Buy
93,664
+3,524
+4% +$264K 0.49% 52
2019
Q2 		$7.41M Buy
90,140
+3,623
+4% +$258K 0.51% 50
2019
Q1 		$6.1M Buy
86,517
+6,665
+8% +$392K 0.44% 53
2018
Q4 		$3.6M Buy
79,852
+9,640
+14% +$505K 0.29% 66
2018
Q3 		$3.97M Buy
70,212
+10,212
+17% +$625K 0.26% 60
2018
Q2 		$4.01M Buy
60,000
+10,783
+22% +$673K 0.28% 57
2018
Q1 		$2.87M Buy
49,217
+9,730
+25% +$618K 0.21% 63
2017
Q4 		$2.54M Buy
39,487
+2,593
+7% +$161K 0.19% 62
2017
Q3 		$1.94M Buy
36,894
+14,280
+63% +$681K 0.15% 63
2017
Q2 		$1.06M Buy
22,614
+7,084
+46% +$342K 0.08% 82
2017
Q1 		$769K Buy
+15,530
New +$872K 0.06% 86

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ranger Investment Management's ANIP Position: Q1 2026 in Review

Ranger Investment Management reduced its ANI Pharmaceuticals (ANIP) stake by 0.63% in Q1 2026, selling an estimated $179K and leaving 360,083 shares worth $27.7M. The position accounts for 2% of the portfolio, ranked #13.

Ranger Investment Management first reported a position in ANIP in Q1 2017 and has held it in 37 quarters since. The position peaked at $38.3M in Q1 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Ranger Investment Management held 360,083 shares of ANI Pharmaceuticals worth $27.7M as of Q1 2026.
  • Ranger Investment Management sold 2,295 ANI Pharmaceuticals shares in Q1 2026, an estimated $179K.
  • ANI Pharmaceuticals made up 2% of Ranger Investment Management's portfolio in Q1 2026, its #13 holding.
  • Ranger Investment Management first reported a position in ANI Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
  • Ranger Investment Management's ANI Pharmaceuticals position peaked at $38.3M in Q1 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Ranger Investment Management's 13F filing for Q1 2026, filed 15 May 2026.